Replies to post #2944 on Synaptogenix Inc (SNPX)

[runncoach]

What about the cancer patients who took the drug for 2.5 years at much more potent doses and more frequently? Some don't seem to understand there is a huge difference between treating for cancer 10+ years ago and what has been learned for memory treatment. The link I posted from today was from 2011. Here's the quote from the article: "Fortunately, this search has been extremely productive, yielding many new drugs that
show no toxicity, are small and not difficult to synthesize, and
address virtually every aspect of AD in the most difficult AD mouse
models of the disease. This PKC activator platform has the following
beneficial effects to prevent and/or halt the progression of:
1. Cognitive Deficits
2. Elevation of Aß
3. Synaptic Loss
4. Amyloid Plaques
5. Neurofibrillary Tangles
6. Neuronal Loss

If someone can show me serious toxic issues since Dr Alkon wrote that article, I'll give it a look. CEO Wilkes said myalgia treated with tylenol.


This trial will bring more clarity than any trial to date in the moderate to severe patient population if objective test scores show statistically significant improvement. That's the advantage of tackling something that few have dared to tackle. If we fail, we fail but it won't be because the science isn't solid. JMHO

[InTheTrenches]

If we have positive results in Phase 2b, then we're in an enviable position. We will have a drug that works in one disease, and the mechanism of action and preclinical results suggest that it will work in multiple diseases. Neurotrope is looking at a lot of blue sky, blu:

- Moderate-to-severe Alzheimer's
- Mild-to-moderate Alzheimer's
- Fragile-X syndrome
- Rhett's syndrome
- Traumatic brain injury
- Stroke

I haven't bothered to look at the addressable market in each of the above diseases, but I imagine the total is several billion $.

You're $10 prediction is ridiculously low, if we have positive results.

Oh, and I forgot to mention no competition for years, and an FDA that wants to get drugs quickly to market that successfully treat Alzheimer's.

[Maple tree]

You mean should run phase2a or 2b for for two years. I am sure you probably like what avxl is doing. Bryostatin has been tested for cancer research for a long time and people or NTRP should know if Bryostatin has major side effect. Or it must be reported in scientific journals. In addition,there will be phase3 for a long term evaluation. Even there will be a issue after phase 3 trial, NTRP still has other PUFA candidates some of which is more effective than Bryostatin
I would not worry about Bryostatin and only thing I want is that Bryostatin works in patient. If Bryostatin works, it proves PKC is a key regulator of Alzheimer and then PUFA will take care of all other issues.